YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$15.39 USD
+0.22 (1.45%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $15.41 +0.02 (0.13%) 7:48 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Cash flow Statements
Fiscal Year End for YmAbs Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -21.43 | -95.57 | -55.28 | -119.34 | -81.03 |
Depreciation/Amortization & Depletion | 0.74 | 0.84 | 0.78 | 0.40 | 0.17 |
Net Change from Assets/Liabilities | -19.73 | -10.37 | -7.28 | 3.44 | 2.67 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 13.19 | 29.18 | -40.78 | 24.27 | 4.70 |
Net Cash From Operating Activities | -27.23 | -75.92 | -102.56 | -91.23 | -73.50 |
Property & Equipment | 0.00 | 0.00 | -0.67 | -0.18 | -1.97 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 61.71 | -2.61 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 61.04 | -2.79 | -1.97 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.10 | 0.08 | 108.31 | 2.00 | 134.70 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.10 | 0.08 | 108.31 | 2.00 | 134.70 |
Effect of Exchange Rate Changes | 0.01 | 0.04 | 0.13 | -0.49 | 0.02 |
Net Change In Cash & Equivalents | -27.13 | -75.80 | 66.93 | -92.50 | 59.27 |
Cash at Beginning of Period | 105.76 | 181.56 | 114.63 | 207.14 | 147.87 |
Cash at End of Period | 78.64 | 105.76 | 181.56 | 114.63 | 207.14 |
Diluted Net EPS | -0.49 | -2.19 | -1.28 | -2.97 | -2.30 |
Fiscal Year End for YmAbs Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -15.88 | -6.63 | -21.43 | -20.44 | -12.69 |
Depreciation/Amortization & Depletion | 0.31 | 0.16 | 0.74 | 0.57 | 0.41 |
Net Change from Assets/Liabilities | 4.38 | -1.35 | -19.73 | -10.29 | -13.72 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 8.01 | 4.34 | 13.19 | 10.96 | 8.15 |
Net Cash From Operating Activities | -3.18 | -3.48 | -27.23 | -19.20 | -17.86 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.35 | 0.59 | 0.10 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 2.35 | 0.59 | 0.10 | 0.00 | 0.00 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
Net Change In Cash & Equivalents | -0.83 | -2.89 | -27.13 | -19.19 | -17.85 |
Cash at Beginning of Period | 78.64 | 78.64 | 105.76 | 105.76 | 105.76 |
Cash at End of Period | 77.81 | 75.75 | 78.64 | 86.57 | 87.91 |
Diluted Net EPS | -0.21 | -0.15 | -0.02 | -0.18 | -0.14 |